Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill hopes to tame rare blood cancer in japanese patients

NCT ID NCT07387471

Ongoing Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study tests a cancer pill called venetoclax in 14 Japanese adults with a rare blood cancer (Waldenström macroglobulinemia) that has come back or not responded to treatment. Participants take the drug by mouth daily, with doses slowly increased. The main goal is to see how many patients have a major reduction in their cancer. The study lasts about 28 months and involves regular check-ups and blood tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Venetoclax (a targeted cancer pill)
What this could lead to
If successful, this could offer a new oral treatment option for Japanese patients with Waldenström macroglobulinemia that has stopped responding to prior therapy.
What could go wrong
This is a small, early-phase study (14 people) with no placebo comparison. The drug may not work as hoped, and side effects like low blood counts or infections are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOPLASMACYTIC LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lymphoma, B-Cell, Marginal Zone lymphoplasmacytic lymphoma neoplasm Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOPLASMACYTIC LYMPHOMA WALDENSTROM MACROGLOBULINEMIA

Contacts and locations

Locations

  • Chiba Cancer Center /ID# 279177

    Chiba, 260-0801, Japan

  • Gunma University Hospital /ID# 277576

    Maebashi, Gunma, 371-8511, Japan

  • Hiroshima University Hospital /ID# 279172

    Hiroshima, Hiroshima, 734-8551, Japan

  • Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital /ID# 279178

    Nagoya, Aichi-ken, 466-8650, Japan

  • Japanese Red Cross Medical Center /ID# 277577

    Shibuya-ku, Tokyo, 150-8935, Japan

  • Kindai University Hospital /ID# 277587

    Sakai-shi, Osaka, 590-0197, Japan

  • Kyushu University Hospital /ID# 277582

    Fukuoka, Fukuoka, 812-8582, Japan

  • NHO Mito Medical Center /ID# 279175

    Higashiibaraki-gun, Ibaraki, 311-3193, Japan

  • Nagano Red Cross Hospital /ID# 279774

    Nagano, 380-8582, Japan

  • Nagoya City University Hospital /ID# 277580

    Nagoya, Aichi-ken, 467-8602, Japan

  • National Cancer Center Hospital /ID# 279076

    Chuo-Ku, Tokyo, 104-0045, Japan

  • National Hospital Organization Disaster Medical Center /ID# 277741

    Tachikawa, Tokyo, 190-0014, Japan

  • The Cancer Institute Hospital Of JFCR /ID# 277579

    Koto-ku, Tokyo, 135-8550, Japan

  • The University of Tokyo Hospital /ID# 279174

    Bunkyo-ku, Tokyo, 113-8654, Japan

  • University Hospital Kyoto Prefectural University of Medicine /ID# 277584

    Kyoto, Kyoto, 602-8566, Japan

  • University of Fukui Hospital /ID# 279173

    Yoshida-gun, Fukui, 910-1104, Japan

  • University of Yamanashi Hospital /ID# 279179

    Chuo-shi, Yamanashi, 409-3898, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.